AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20082715 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin alone
Number of subjects: 36
Study 20082715 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole alone
Number of subjects: 36
Study 20082715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of melatonin and omeprazole
Number of subjects: 36
Study 20082715 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study 18363810 — intervention group
Group type: EXPERIMENTAL
Intervention: Down's syndrome individuals (DS)
Number of subjects: 14
Study 18363810 — intervention group
Group type: COMPARATOR
Intervention: Controls (CONT)
Number of subjects: 14
Study 16137357 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 61
Study 16137357 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 61
Study 12207630 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml)
Number of subjects: 10
Study 12207630 — intervention group
Group type: COMPARATOR
Intervention: Tap water (200 ml)
Number of subjects: 10
Study 10792845 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (0.3 mg/ml, 3 times a week for 12 weeks)
Number of subjects: 11
Study 10792845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8777829 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-enriched (5%) gas mixture with low-dose scopolamine (scopoderm TTS)
Number of subjects: 8
Study 8777829 — intervention group
Group type: COMPARATOR
Intervention: Voluntary hyperventilation with low-dose scopolamine (scopoderm TTS)
Number of subjects: 8
Study 8777829 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-enriched (5%) gas mixture without scopolamine
Number of subjects: 8
Study 8777829 — intervention group
Group type: COMPARATOR
Intervention: Voluntary hyperventilation without scopolamine
Number of subjects: 8
Study 1501087 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned extracapsular extraction with PMMA IOL implantation (11 mm incision)
Number of subjects: 120
Study 1501087 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with PMMA IOL implantation (7 mm incision)
Number of subjects: 120
Study 1501087 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with foldable silicone single‐piece IOL implantation (4 mm incision)
Number of subjects: 120
Study 1501087 — intervention group
Group type: COMPARATOR
Intervention: Age-matched normal controls
Number of subjects: 120
Study 6097665 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (40 mg) in fasting state
Number of subjects: 12
Study 6097665 — intervention group
Group type: COMPARATOR
Intervention: Enalapril maleate (40 mg) with a standard breakfast
Number of subjects: 12
Study 31729825 — intervention group
Group type: EXPERIMENTAL
Intervention: Baerveldt glaucoma implant (BGI)
Number of subjects: 119
Study 31729825 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (TE)
Number of subjects: 119
Study 31851542 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS team training (6 hours) and implementation of teamwork tools and strategies (12 months)
Number of subjects: 0
Study 31851542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29908803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed milk allowance (FIX) of 6 to 8 L/d from day 1 after birth
Number of subjects: 1264
Study 29908803 — intervention group
Group type: COMPARATOR
Intervention: Slowly increasing milk allowance (INC) starting from 4 to 5 L/d to reach 6 to 8 L/d over 7 to 14 days
Number of subjects: 1264
Study 29908803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed milk allowance (FIX)
Number of subjects: 1264
Study 29908803 — intervention group
Group type: COMPARATOR
Intervention: Both FIX and INC groups
Number of subjects: 1264
Study 27931254 — intervention group
Group type: EXPERIMENTAL
Intervention: STAK-D intervention website and wrist-worn activity monitor for 6 months
Number of subjects: 50
Study 27931254 — intervention group
Group type: EXPERIMENTAL
Intervention: STAK-D intervention
Number of subjects: 50
Study 24725515 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback using wireless technology
Number of subjects: 40
Study 24725515 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback using wireless technology (post-implementation)
Number of subjects: 40
Study 24725515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 22652379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato paste supplementation (70 g containing 33.3 mg of lycopene)
Number of subjects: 19
Study 22652379 — intervention group
Group type: COMPARATOR
Intervention: Control (no tomato paste added to regular diet)
Number of subjects: 19
Study 22652379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato paste supplementation
Number of subjects: 19
Study 20116300 — intervention group
Group type: EXPERIMENTAL
Intervention: First RCT (N = 244)
Number of subjects: 345
Study 20116300 — intervention group
Group type: EXPERIMENTAL
Intervention: Second RCT (N = 101)
Number of subjects: 345
Study 18544158 — intervention group
Group type: EXPERIMENTAL
Intervention: LIGHT (40% peak oxygen consumption, VO2peak)
Number of subjects: 46
Study 18544158 — intervention group
Group type: COMPARATOR
Intervention: MODERATE (60% VO2peak)
Number of subjects: 46
Study 18544158 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 46
Study 16115357 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg elemental Cu/d as CuSO4
Number of subjects: 16
Study 16115357 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg elemental Cu/d as CuSO4
Number of subjects: 16
Study 16115357 — intervention group
Group type: COMPARATOR
Intervention: 0 mg elemental Cu/d (control)
Number of subjects: 16
Study 12423712 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 129
Study 12423712 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 129
Study 12423712 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan vs Atenolol
Number of subjects: 129
Study 10524892 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy alone
Number of subjects: 184
Study 10524892 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus mitomycin C
Number of subjects: 184
Study 7591024 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 127
Study 7591024 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 127
Study 7591024 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification education control
Number of subjects: 127
Study 1722167 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 alpha-reductase inhibitor); varying doses administered to men with benign prostatic hyperplasia.
Number of subjects: 0
Study 6638144 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative activity
Number of subjects: 0
Study 6638144 — intervention group
Group type: COMPARATOR
Intervention: Imitation activity
Number of subjects: 0
Study 6638144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive types
Number of subjects: 0
Study 6638144 — intervention group
Group type: COMPARATOR
Intervention: Sensing types
Number of subjects: 0
Study 28925286 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage VFE (four times)
Number of subjects: 28
Study 28925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dosage VFE (twice)
Number of subjects: 28
Study 28925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage VFE (once)
Number of subjects: 28
Study 30418882 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized Ankle Stretcher (MAS)
Number of subjects: 16
Study 30418882 — intervention group
Group type: COMPARATOR
Intervention: Stretching board (Control)
Number of subjects: 16
Study 26903058 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A injection
Number of subjects: 80
Study 26903058 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study 23828145 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Number of subjects: 910
Study 23828145 — intervention group
Group type: COMPARATOR
Intervention: Risedronate alone (2.5 mg/day or 17.5 mg/week)
Number of subjects: 910
Study 19789648 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery system
Number of subjects: 964
Study 19789648 — intervention group
Group type: COMPARATOR
Intervention: Facility-based delivery system
Number of subjects: 964
Study 15208869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy helium-neon laser exposure and decimeter electromagnetic radiation (DMEM)
Number of subjects: 58
Study 15208869 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEM-therapy
Number of subjects: 58
Study 11290635 — intervention group
Group type: EXPERIMENTAL
Intervention: Home chemotherapy
Number of subjects: 87
Study 11290635 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 87
Study 9327116 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Pocket (AP) rebreather
Number of subjects: 0
Study 9327116 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Term Air Supply System (STASS) mini SCUBA set
Number of subjects: 0
Study 8098951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (droperidol and fentanyl)
Number of subjects: 100
Study 8098951 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 100
Study 8098951 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100
Study 8098951 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 100
Study 8098951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 8098951 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 100
Study 3307061 — intervention group
Group type: COMPARATOR
Intervention: Antilymphoblast globulin (ALG), azathioprine (AZA), and prednisone (P)
Number of subjects: 173
Study 3307061 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) plus prednisone
Number of subjects: 173
Study 3307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azathioprine, cyclosporine, and prednisone (+/- ALG)
Number of subjects: 173
Study 3307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic patients
Number of subjects: 173
Study 3307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (>45 years)
Number of subjects: 173
Study 3307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier patients (>70 kg)
Number of subjects: 173
Study 3307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients of cadaveric allografts
Number of subjects: 173
Study 3307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients hospitalized for infections
Number of subjects: 173
Study 30489432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calfactant (8.0 mg/ml)
Number of subjects: 18
Study 30489432 — intervention group
Group type: COMPARATOR
Intervention: Low-dose calfactant (0.8 mg/ml)
Number of subjects: 18
Study 30489432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29523450 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional early dose of measles vaccine (MV) 4 weeks after the third dose of DTP-containing Pentavalent vaccine and standard MV at 9 months
Number of subjects: 4496
Study 29523450 — intervention group
Group type: COMPARATOR
Intervention: Standard measles vaccine (MV) at 9 months (control)
Number of subjects: 4496
Study 29523450 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional early dose of measles vaccine (MV) in children not exposed to an OPV campaign after enrolment
Number of subjects: 4496
Study 26498324 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab therapy
Number of subjects: 50
Study 24683472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of β2‐microglobulin (B2M)
Number of subjects: 0
Study 24683472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of fibroblast growth factor 23 (FGF23)
Number of subjects: 0
Study 24683472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of interleukin‐8 (IL‐8)
Number of subjects: 0
Study 24683472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of IL‐18
Number of subjects: 0
Study 24683472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of IL‐2 receptor alpha (IL‐2 RA)
Number of subjects: 0
Study 24683472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma levels of tumour necrosis factor receptor type I
Number of subjects: 0
Study 22078632 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinyl estradiol (EE)/150 mcg levonorgestrel (LNG)
Number of subjects: 109
Study 22078632 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg EE/100 mcg LNG
Number of subjects: 109
Study 22078632 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose pill (30 mcg EE/150 mcg LNG)
Number of subjects: 109
Study 22078632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose pill (20 mcg EE/100 mcg LNG)
Number of subjects: 109
Study 19293263 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP (0.3 microg/kg) infused over 20 min after a 12-h period of water deprivation
Number of subjects: 45
Study 19293263 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoalbuminuric type 1 diabetic patients without DR)
Number of subjects: 45
Study 19293263 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP administration
Number of subjects: 45
Study 17712402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal LIPO-4 vaccine (0.1 ml, 100 microg of each peptide)
Number of subjects: 68
Study 17712402 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular LIPO-4 vaccine (0.5 ml, 500 microg of each peptide)
Number of subjects: 68
Study 15256991 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% indomethacin solution
Number of subjects: 135
Study 15256991 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.1% fluorometholon acetate
Number of subjects: 135
Study 15256991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study 11280194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka-derived varicella vaccines administered post-exposure within 3 days of rash onset
Number of subjects: 0
Study 11280194 — intervention group
Group type: COMPARATOR
Intervention: Varilrix and Varivax II
Number of subjects: 0
Study 9272811 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg p.o.)
Number of subjects: 10
Study 9272811 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (600 mg/day) with Morphine
Number of subjects: 10
Study 7946690 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/ml
Number of subjects: 147
Study 7946690 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml
Number of subjects: 147
Study 3364226 — intervention group
Group type: EXPERIMENTAL
Intervention: Disguised alcohol
Number of subjects: 0
Study 3364226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alcohol conditioning)
Number of subjects: 0
Study 3364226 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (with expectancy of tonic water)
Number of subjects: 0
Study 29791437 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel dressing
Number of subjects: 230
Study 29791437 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing (Control)
Number of subjects: 230
Study 26580307 — intervention group
Group type: EXPERIMENTAL
Intervention: Light monotherapy (10,000-lux fluorescent white light box for 30 min/d in the early morning plus placebo pill)
Number of subjects: 122
Study 26580307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy (inactive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d)
Number of subjects: 122
Study 26580307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (light and antidepressant)
Number of subjects: 122
Study 26580307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive negative ion generator plus placebo pill)
Number of subjects: 122
Study 26342028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg) daily for 14 days
Number of subjects: 34
Study 26342028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg)/isoniazid (300 mg) daily for 14 days
Number of subjects: 34
Study 26342028 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (600 mg)/isoniazid (300 mg) after washout
Number of subjects: 34
Study 26342028 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (600 mg) after washout
Number of subjects: 34
Study 23945074 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40
Study 23945074 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 40
Study 20683270 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG/COBI 150 mg/FTC/TDF
Number of subjects: 44
Study 20683270 — intervention group
Group type: COMPARATOR
Intervention: FTC + TDF
Number of subjects: 44
Study 18389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Notched jig
Number of subjects: 0
Study 18389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontrimmed, square microspecimens
Number of subjects: 0
Study 18389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Square specimens of 1 mm2
Number of subjects: 0
Study 18389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining dentin thickness
Number of subjects: 0
Study 18389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Microspecimen gluing protocol
Number of subjects: 0
Study 18389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosshead speed
Number of subjects: 0
Study 16786387 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 40
Study 16786387 — intervention group
Group type: COMPARATOR
Intervention: Control group (same osteoporosis drug therapy)
Number of subjects: 40
Study 16786387 — intervention group
Group type: EXPERIMENTAL
Intervention: New traumatic vertebral body fractures (managed by fixateur interne alone or combination with kyphoplasty)
Number of subjects: 40
Study 12648731 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12648731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11998139 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy methods for urinary incontinence
Number of subjects: 0
Study 11998139 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9027944 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for pelvic and periaortic irradiation
Number of subjects: 0
Study 9027944 — intervention group
Group type: COMPARATOR
Intervention: Prone position for pelvic and periaortic irradiation
Number of subjects: 0
Study 9027944 — intervention group
Group type: COMPARATOR
Intervention: Prone position with a belly board
Number of subjects: 0
Study 1524963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of pyridostigmine (30 mg three times daily)
Number of subjects: 47
Study 1524963 — intervention group
Group type: COMPARATOR
Intervention: Transdermal hyoscine patches
Number of subjects: 47
Study 3890160 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with hip joint distension arthrography
Number of subjects: 38
Study 3890160 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study 31766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural individual low-FODMAP dietary advice (SILFD)
Number of subjects: 62
Study 31766497 — intervention group
Group type: COMPARATOR
Intervention: Brief advice on a commonly recommended diet (BRD)
Number of subjects: 62
Study 29346228 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined obturator nerve and femoral triangle blockade (OFB)
Number of subjects: 74
Study 29346228 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 74
Study 26081648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model containing all carotenoids and vitamin C
Number of subjects: 30
Study 26081648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C only model
Number of subjects: 30
Study 26081648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein only model
Number of subjects: 30
Study 26081648 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based upon factor analysis
Number of subjects: 30
Study 24655714 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat (PUFA) intake
Number of subjects: 234
Study 24655714 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat
Number of subjects: 234
Study 24655714 — intervention group
Group type: COMPARATOR
Intervention: Total fat and carbohydrates
Number of subjects: 234
Study 22000576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based navigation system
Number of subjects: 80
Study 22000576 — intervention group
Group type: COMPARATOR
Intervention: Imageless navigation system with surface registration
Number of subjects: 80
Study 20185416 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus 10 sessions of biofeedback-assisted relaxation training (BART)
Number of subjects: 20
Study 20185416 — intervention group
Group type: COMPARATOR
Intervention: Standardized medication treatment
Number of subjects: 20
Study 17919380 — intervention group
Group type: EXPERIMENTAL
Intervention: HTEA (high thoracic epidural anesthesia) with 0.5% lidocaine 3 ‐ 5 ml every two hours for one month
Number of subjects: 117
Study 17919380 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine medication)
Number of subjects: 117
Study 17919380 — intervention group
Group type: EXPERIMENTAL
Intervention: HTEA
Number of subjects: 117
Study 15616092 — intervention group
Group type: EXPERIMENTAL
Intervention: FTST
Number of subjects: 150
Study 15616092 — intervention group
Group type: EXPERIMENTAL
Intervention: PVCT
Number of subjects: 150
Study 15616092 — intervention group
Group type: COMPARATOR
Intervention: LAT
Number of subjects: 150